Summary Previous work has implicated putative tumour-suppressor (ts) genes at 6q27 and a broad region at 6pl2-q23. Here 
Tumour progression involves the activation of oncogenes and the loss of tumour suppressors. Clues to the location of tumour-suppressor (ts) genes come from observed nonrandom chromosome deletions that may indicate loss of a wild-type allele allowing expression of a recessive mutated form of the tumour-suppressor gene on the other homologue, a molecular version of Knudsen's two-hit hypothesis for cancer induction (Knudsen, 1971) . In retinoblastoma, which provided support for the two-hit hypothesis, alterations in the RBI gene alone are sufficient to produce tumours. However, it is now clear that for many other types of tumours, including ovarian carcinomas, malignancy is the result of events occurring in multiple genes (Fearon and Vogelstein, 1990; Dodson et al., 1993) . The elucidation of these events in ovarian cancer is still at an early stage, but the results we report here highlight the involvement of at least two, possibly four, ts genes on the long arm of chromosome 6.
Frequent non-random deletions of chromosome 6q have been observed in primary ovarian tumours, both cytogenetically (Pejovic et al., 1992; Thompson et al., 1994) and at the molecular level by loss of constitutional heterozygosity (LOH; Ehlen and Dubeau, 1990; Lee et at., 1990; Zheng et al., 1991; Dodson et al., 1993 A second region of deletion spanning 6ql2-q23 was suggested by Cliby et al. (1993) . We have sought to define this region more precisely by performing a study of the allelotypes of coded blood-tumour DNAs from 40 patients with ovarian tumours using highly polymorphic dinucleotide repeat microsatellites. The study provides preliminary evidence of the involvement of 6ql3-q23 in benign and endometrioid tumours and also confirms the involvement of the distal region in serous tumours.
Materials and methods

Patients and tissues
The study samples comprised 40 tumours classified as ten benign, three borderline mucinous cystadenocarcinomas, four mucinous carcinomas, 12 serous carcinomas and 11 endometrioid carcinomas. Tumours were staged according to the FIGO (1971) classification, and tumour-rich areas were dissected from surgically resected material and stored for DNA extraction by snap freezing in liquid nitrogen. High molecular weight DNA was prepared from tumour and peripheral blood samples from each of the 40 patients by the sodium dodecylsulphate (SDS)-proteinase K and phenolchloroform method (Sambrook et al., 1989) . Samples were coded in Belfast and sent to Manchester for analysis.
Analysis of alleles Two markers (D6S355 and D6S359) were isolated and characterised in our laboratory and seven markers (D6S280, D6S275, D6S284, D6S286, D6S287, D6S300 and D6S313) were genetically mapped by others (Weissenbach et al., 1992 al. (1994a,b) and are shown in Figure 1. (CA). microsatellites for D6S186 and D6S193, at 6q26 and 6q27 respectively (Saito et al., 1992b) , were isolated from cosmids generously provided by Dr Y Nakamura using the method of Santibanez-Koref et al. (1993) . The primers, annealing temperatures and product sizes of these markers were reported recently (Orphanos et al., 1995) .
Polymerase chain reactions and the analysis of alleles by phosphoimager have been described (Orphanos et al., , 1995 Of ten benign tumours, five had no AI and five had Al at 1-3 loci. The most frequent site of imbalance was D6S287 at 6q21 -q22.3, which was observed in four of seven samples (57%).
The pattern of AI in three borderline mucinous cystadenocarcinomas was specific to the particular tumour: tumour 29 showed no imbalance, tumour 11 showed imbalance at a single locus (D6S275) and tumour 20 showed imbalance at four loci in two separate regions.
No Al was observed in the four mucinous tumours analysed.
In serous tumours, extensive imbalance involving more than three loci was observed in five tumours (5, 27, 40, 42, 44) of FIGO stage III. However, we also observed no imbalance in another three tumours (14, 15, 41) from patients with stage III disease. The region showing highest imbalance in serous tumours was at 6q26-q27, where imbalance at D6S186 was observed in 5/8 informative patients (62%), and at D6S193, where 6/8 informative patients (75%) showed imbalance: Al occurred at one or other of these loci in 7/10 informative patients.
Endometrioid tumours, in contrast, showed AI frequencies at D6S186 and D6S193 of 2/7 and 2/9 informative cases respectively, a combined frequency of 3/11 that was considerably less than that of the serous tumours. However, endometrioid tumours showed high frequencies of Al at D6S287 (5/8 = 62%), the locus involved in some benign tumours, and at D6S284 (5/7 = 71%) located at 6q14-q15. (Osborne and Leech, 1994) .
Interpretation is also dependent on the accurate ordering of loci. The order shown in Figure 1 is in accord with the consensus map that resulted from the Second International Chromosome 6 Workshop (Volz et al., 1994 mative patients (numbers 20, 40, 38) places D6S297 distal to D6S193.
When the data for all patients are considered (Table I) , the frequency of Al is seen to vary from 10% to 43% between loci, with D6S287 appearing as the most frequently involved locus (43%). However, when classified according to histological type, the results appear more informative. Only the group of four mucinous tumours failed to show AI, in agreement with previous molecular observations (Saito et al., 1992a; Foulkes et al., 1993) and the cytogenetic observation that most well-differentiated mucinous tumours have normal karyotypes (Pejovic et al., 1992) .
With serous tumours the highest Al was observed at 6q26-q27 with D6S186 and D6S193, which together showed 70% AI. These observations support the findings of Saito et al. (1992a) that imbalance occurs at high frequency close to D6S193. We did not test D6S149 (the other flanking RFLP used by Saito et al., 1992a) in this study because we were unable to isolate a dinucleotide repeat sequence from cosmid cC16-24. Although Al was often very extensive in stage II and IV serous tumours, four tumours (14, 15, 41 and 38) showed no Al. This suggests that deletions of chromosome 6q are not obligatory in the progression of serous tumours, although, of course, deletions may be present at loci we have not examined. With the application of an increasing density of markers it is likely that the frequency of interstitial deletions, already high, may increase owing to the detection of random events. Our data also show evidence for the involvement of proximal 6q, possibly at three distinct regions: in early-stage tumours at D6S275-D6S300 and in endometrioid tumours around D6S287 and also at D6S284.
Early-stage tumours from patients 18 (benign), 11 (borderline) and 13 (serous stage I) had minor regions of AI that suggested a smallest region of deletion between D6S275 and D6S300 (0.9cM; Volz et al., 1994) . Of the tumours that showed AI at any locus, this region may be involved in 3/5 benign tumours, 3/3 borderline tumours, 7/10 serous tumours and 5/9 endometrioid tumours.
The involvement of D6S287 (6q21-q22.3) in all four benign tumours and in 6/9 endometrioid tumours that showed Al at any locus suggests that this region may be involved early in the progression of endometrioid tumours. Imbalance at D6S284 (6ql4-ql5) also occurred at high frequency (71%) in endometrioid tumours, but at low frequencies in borderline and serous tumours (33% and 20% respectively) and not at all in benign tumours. The distance between D6S287 and D6S284 is large (at least 10.9 cM, the separation of Genethon marker D6S300, closest to D6S287, and D6S284; Volz et al., 1994) ; however, because of the small sample sizes of these subgroups, we cannot be certain that the results indicate the presence of separate putative tumour suppressors within this region.
The presence of a tumour suppressor(s) in the proximal half of 6q was also suggested by other recent studies from our laboratory. Deletion of a region containing D6S246 at 6ql6.3 was demonstrated by fluorescence in situ hybridisation in one of two chromosome 6 homologues in blood lymphocytes from patients with acute lymphocytic leukaemia (ALL) (Menasce et al., 1994b) and non-Hodgkin's lymphoma (NHL) (Menasce et al., 1994a) patients previously diagnosed as having del (6q). A study of AI in breast tumours (Orphanos et al., 1995) yielded results similar to that obtained here, i.e. the involvement of a large part of proximal 6q and of 6q26-q27. As in the present group of endometrioid tumours, the proximal 6q region appears relatively more important in malignant breast tumours than the distal region.
In conclusion, the results of this study provide preliminary evidence which needs to be confirmed with a larger cohort of samples, for the involvement of at least two regions of chromosome 6q in the progression of different histological types of tumour. Only mucinous tumours appear not to have 6q involvement.
